We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ROVI.MC

Price
48.34
Stock movement up
+0.38 (0.79%)
Company name
Laboratorios Farmaceuticos ROVI
Exchange
(MC
,
Currency
EUR
)
Sector
Healthcare >
Biotechnology
Market cap
2.47B
Ent value
2.80B
Price/Sales
3.18
Price/Book
5.12
Div yield
-
Div growth
-
Growth years
-
FCF payout
198.96%
Trailing P/E
16.70
Forward P/E
14.37
PEG
-
EPS growth
59.01%
1 year return
-39.16%
3 year return
-7.99%
5 year return
14.56%
10 year return
12.92%
Last updated: 2025-04-12

DIVIDENDS

ROVI.MC does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E16.70
Price to OCF27.34
Price to FCF71.12
Price to EBITDA11.35
EV to EBITDA12.87

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales3.18
Price to Book5.12
EV to Sales3.60

FINANCIALS

Per share

Per share data
Current share count51.15M
EPS (TTM)2.77
FCF per share (TTM)0.65

Income statement

Income statement data
Revenue (TTM)778.00M
Gross profit (TTM)470.81M
Operating income (TTM)191.53M
Net income (TTM)148.03M
EPS (TTM)2.77
EPS (1y forward)3.36

Margins

Margins data
Gross margin (TTM)60.52%
Operating margin (TTM)24.62%
Profit margin (TTM)19.03%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash44.58M
Net receivables120.83M
Total current assets540.78M
Goodwill-5.94M
Intangible assets27.09M
Property, plant and equipment500.08M
Total assets857.33M
Accounts payable80.88M
Short/Current long term debt121.16M
Total current liabilities272.45M
Total liabilities374.56M
Shareholder's equity482.76M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)90.46M
Capital expenditures (TTM)55.69M
Free cash flow (TTM)34.77M
Dividends paid (TTM)69.18M

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity30.66%
Return on Assets17.27%
Return on Invested Capital29.27%
Cash Return on Invested Capital6.87%

STOCK INFORMATION

Stock chart

Stock price data
Open48.54
Daily high48.62
Daily low47.48
Daily Volume150K
All-time high91.50
1y analyst estimate92.01
Beta0.48
EPS (TTM)2.77
Dividend per share-
Ex-div date8 Jul 2024
Next earnings date6 May 2025

Downside potential

Downside potential data
ROVI.MCS&P500
Current price drop from All-time high-47.17%-12.89%
Highest price drop-67.18%-56.47%
Date of highest drop6 Mar 20099 Mar 2009
Avg drop from high-25.20%-11.07%
Avg time to new high28 days12 days
Max time to new high1773 days1805 days
COMPANY DETAILS
ROVI.MC (Laboratorios Farmaceuticos ROVI) company logo
Marketcap
2.47B
Marketcap category
Mid-cap
Description
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Employees
2111
Website
https://www.rovi.es
Investor relations
-
SEC filings
ROVI.MC SEC filings
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
3 Stocks That May Be Priced Below Their Estimated Value In January 2025
As global markets navigate a mixed economic landscape marked by resilient labor markets and inflationary pressures, investors are closely monitoring the impact of these factors on stock valuations. Wi...
January 13, 2025
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved